{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:09:13Z","timestamp":1789398553367,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM), a plasma cell malignancy, despite the progress in treatment, is still a challenge for both clinicians and affected patients. Modern treatment regimens including monoclonal antibodies, bispecific antibodies, CAR-T cell therapy as well as new generations of immunomodulatory drugs and proteasome inhibitors significantly improved clinical outcomes. Nonetheless, there is still a room for improvement and novel therapeutic strategies. IL-17-related signaling is a relatively undiscovered area in MM research. It was established that IL-17 is the growth factor for plasma cells including their malignant counterparts, is associated with myelomagenesis and disease progression. Furthermore, IL-17 axis can be pharmacologically targeted by monoclonal antibodies currently being used in different indications. In this narrative review we summarized the role of IL-17 axis in MM. Specifically, we focused on the role of IL-17 in MM development and progression with a particular emphasis upon clinical implications. Moreover, we have briefly summarized the potential role of therapeutic interference with IL-17-related singling and have outlined future research directions.<\/jats:p>","DOI":"10.1007\/s10238-025-01728-6","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:42:40Z","timestamp":1749465760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of IL-17-related signaling in myelomagenesis, disease prognosis\/progression, and therapeutic approach\u2014a scoping review"],"prefix":"10.1007","volume":"25","author":[{"given":"Piotr","family":"Kulig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ra\u0142owiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart\u0142omiej","family":"Baumert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogus\u0142aw","family":"Machali\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma. Blood [Internet]. 2008;111(6):2962\u201372. Available from: https:\/\/ashpublications.org\/blood\/article\/111\/6\/2962\/24148\/Multiple-myeloma","DOI":"10.1182\/blood-2007-10-078022"},{"key":"1728_CR2","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology [Internet]. 2014;15(12):e538\u201348. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204514704425","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"1728_CR3","doi-asserted-by":"crossref","unstructured":"Riccardi A, Gobbi PG, Ucci G, Bertoloni D, Luoni R, Rutigliano L, et al. Changing clinical presentation of multiple myeloma. European Journal of Cancer and Clinical Oncology [Internet]. 1991;27(11):1401\u20135. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/027753799190020E","DOI":"10.1016\/0277-5379(91)90020-E"},{"issue":"1","key":"1728_CR4","first-page":"34","volume":"101","author":"WD Lewis","year":"2020","unstructured":"Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and Treatment. Am Fam Phys. 2020;101(1):34\u201341.","journal-title":"Am Fam Phys"},{"key":"1728_CR5","doi-asserted-by":"crossref","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer Journal [Internet]. 2018;8(1):7. Available from: https:\/\/www.nature.com\/articles\/s41408-017-0037-4","DOI":"10.1038\/s41408-017-0037-4"},{"key":"1728_CR6","doi-asserted-by":"crossref","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Reviews [Internet]. 2021;49:100808. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2100014X","DOI":"10.1016\/j.blre.2021.100808"},{"key":"1728_CR7","doi-asserted-by":"crossref","unstructured":"Ma K, Du W, Xiao F, Han M, Huang E, Peng N, et al. IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. Cellular & Molecular Immunology [Internet]. 2021;18(7):1739\u201350. Available from: https:\/\/www.nature.com\/articles\/s41423-020-00540-4","DOI":"10.1038\/s41423-020-00540-4"},{"key":"1728_CR8","doi-asserted-by":"crossref","unstructured":"Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, et al. Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood [Internet]. 2010;115(26):5385\u201392. Available from: https:\/\/ashpublications.org\/blood\/article\/115\/26\/5385\/130846\/Elevated-IL17-produced-by-Th17-cells-promotes","DOI":"10.1182\/blood-2009-10-246660"},{"key":"1728_CR9","doi-asserted-by":"crossref","unstructured":"Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, Borrello I. A novel role of IL-17\u2013producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood [Internet]. 2010;116(18):3554\u201363. Available from: https:\/\/ashpublications.org\/blood\/article\/116\/18\/3554\/27929\/A-novel-role-of-IL17producing-lymphocytes-in","DOI":"10.1182\/blood-2010-05-283895"},{"key":"1728_CR10","doi-asserted-by":"crossref","unstructured":"Kulig P, \u0141uczkowska K, Machali\u0144ski B, Baumert B. Deep hematologic response to RD treatment in patients with multiple myeloma is associated with overexpression of IL-17R in CD138+ plasma cells. Scientific Reports [Internet]. 2024;14(1):23559. Available from: https:\/\/www.nature.com\/articles\/s41598-024-74558-3","DOI":"10.1038\/s41598-024-74558-3"},{"key":"1728_CR11","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Corrigendum to \u2018Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology [Internet]. 2022;33(1):117. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421044999","DOI":"10.1016\/j.annonc.2021.10.001"},{"key":"1728_CR12","unstructured":"Key Statistics About Multiple Myeloma. Available form: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html."},{"key":"1728_CR13","unstructured":"Cancer Statistics: Myeloma. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"1728_CR14","doi-asserted-by":"publisher","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica [Internet]. 2018;103(9):e412\u20135. Available from: http:\/\/www.haematologica.org\/lookup\/doi\/https:\/\/doi.org\/10.3324\/haematol.2017.183475","DOI":"10.3324\/haematol.2017.183475"},{"key":"1728_CR15","doi-asserted-by":"publisher","unstructured":"Branagan A, Lei M, Lou U, Raje N. Current Treatment Strategies for Multiple Myeloma. JCO Oncology Practice [Internet]. 2020;16(1):5\u201314. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JOP.19.00244","DOI":"10.1200\/JOP.19.00244"},{"key":"1728_CR16","doi-asserted-by":"publisher","unstructured":"Costa L, Medvedova E, Chhabra S, Dholaria B, Dhakal B, Godby K, et al. S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL. HemaSphere [Internet]. 2023;7(S3):e1332195. Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/01.HS9.0000967724.13321.95","DOI":"10.1097\/01.HS9.0000967724.13321.95"},{"key":"1728_CR17","doi-asserted-by":"crossref","unstructured":"Richardson P, Hideshima T, Anderson K. Thalidomide in multiple myeloma. Biomedicine & Pharmacotherapy [Internet]. 2002;56(3):115\u201328. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332202001683","DOI":"10.1016\/S0753-3322(02)00168-3"},{"key":"1728_CR18","doi-asserted-by":"crossref","unstructured":"Charli\u0144ski G, Vesole DH, Jurczyszyn A. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma. Cancers [Internet]. 2021;13(18):4666. Available from: https:\/\/www.mdpi.com\/2072-6694\/13\/18\/4666","DOI":"10.3390\/cancers13184666"},{"issue":"4","key":"1728_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/14656566.2018.1441287","volume":"19","author":"E Scalzulli","year":"2018","unstructured":"Scalzulli E, Grammatico S, Vozella F, Petrucci MT. Proteasome inhibitors for the treatment of multiple myeloma. Exp Opin Pharmacother. 2018;19(4):375\u201386.","journal-title":"Exp Opin Pharmacother"},{"key":"1728_CR20","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. New England Journal of Medicine [Internet]. 2016;375(14):1319\u201331. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1607751","DOI":"10.1056\/NEJMoa1607751"},{"key":"1728_CR21","doi-asserted-by":"publisher","unstructured":"Moreau P, Garfall AL, Van De Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine [Internet]. 2022;387(6):495\u2013505. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa2203478","DOI":"10.1056\/NEJMoa2203478"},{"key":"1728_CR22","doi-asserted-by":"publisher","unstructured":"Pu J, Liu T, Sharma A, Jiang L, Wei F, Ren X, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Experimental Hematology & Oncology [Internet]. 2024;13(1):105. Available from: https:\/\/ehoonline.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40164-024-00576-6","DOI":"10.1186\/s40164-024-00576-6"},{"key":"1728_CR23","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia [Internet]. 2014;28(5):1122\u20138. Available from: https:\/\/www.nature.com\/articles\/leu2013313","DOI":"10.1038\/leu.2013.313"},{"key":"1728_CR24","doi-asserted-by":"publisher","unstructured":"Byun JM, Park S-S, Yoon S-S, Ahn A, Kim M, Lee JY, et al. Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study. Blood Research [Internet]. 2023;58(2):83\u201390. Available from: https:\/\/www.bloodresearch.or.kr\/journal\/view.html?doi=https:\/\/doi.org\/10.5045\/br.2023.2023005","DOI":"10.5045\/br.2023.2023005"},{"key":"1728_CR25","doi-asserted-by":"crossref","unstructured":"Sweeney NW, Ballard EW, Hernandez EF, Espinoza AIR, Vicencio AJC, Flores P\u00e9rez PA, et al. A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy. Blood [Internet]. 2022;140(Supplement 1):7178\u20139. Available from: https:\/\/ashpublications.org\/blood\/article\/140\/Supplement%201\/7178\/488063\/A-Retrospective-Comparison-of-the-Side-Effect","DOI":"10.1182\/blood-2022-170392"},{"key":"1728_CR26","doi-asserted-by":"publisher","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncology [Internet]. 2017;3(1):28. Available from: http:\/\/oncology.jamanetwork.com\/article.aspx?doi=https:\/\/doi.org\/10.1001\/jamaoncol.2016.3160","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"1728_CR27","doi-asserted-by":"crossref","unstructured":"Nunnelee J, Cottini F, Zhao Q, Faisal MS, Elder P, Rosko A, et al. Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma. Journal of Clinical Medicine [Internet]. 2022;11(19):5794. Available from: https:\/\/www.mdpi.com\/2077-0383\/11\/19\/5794","DOI":"10.3390\/jcm11195794"},{"key":"1728_CR28","doi-asserted-by":"crossref","unstructured":"Peipert JD, Zhao F, Lee J-W, Shen S, Ip E, O\u2019Connell N, et al. Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma. JAMA Network Open [Internet]. 2024;7(3):e243854. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2816820","DOI":"10.1001\/jamanetworkopen.2024.3854"},{"key":"1728_CR29","doi-asserted-by":"publisher","unstructured":"Teixeira MX, Reis AMM, Drummond PLDM, Malta JS, Silveira LP, Menezes De P\u00e1dua CA. Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009\u20132020. Annals of Hematology [Internet]. 2024; Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00277-024-05684-1","DOI":"10.1007\/s00277-024-05684-1"},{"key":"1728_CR30","doi-asserted-by":"publisher","unstructured":"Yan W, Xu J, Fan H, Li L, Cui J, Du C, et al. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. Cancer [Internet]. 2024;130(3):421\u201332. Available from: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/cncr.35056","DOI":"10.1002\/cncr.35056"},{"key":"1728_CR31","doi-asserted-by":"crossref","unstructured":"Goldman-Mazur S, Visram A, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Outcomes after biochemical or clinical progression in patients with multiple myeloma. Blood Advances [Internet]. 2023;7(6):909\u201317. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/7\/6\/909\/484885\/Outcomes-after-biochemical-or-clinical-progression","DOI":"10.1182\/bloodadvances.2022007082"},{"key":"1728_CR32","doi-asserted-by":"publisher","unstructured":"McCullough KB, Hobbs MA, Abeykoon JP, Kapoor P. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies. Current Hematologic Malignancy Reports [Internet]. 2018;13(2):114\u201324. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11899-018-0443-0","DOI":"10.1007\/s11899-018-0443-0"},{"key":"1728_CR33","doi-asserted-by":"publisher","unstructured":"Ferreri CJ, Lee HC. Antibody Drug Conjugates in Multiple Myeloma. The Cancer Journal [Internet]. 2022;28(6):488\u201395. Available from: https:\/\/journals.lww.com\/https:\/\/doi.org\/10.1097\/PPO.0000000000000628","DOI":"10.1097\/PPO.0000000000000628"},{"key":"1728_CR34","doi-asserted-by":"publisher","unstructured":"Sidiqi MH, Al Saleh AS, Kumar SK, Leung N, Jevremovic D, Muchtar E, et al. Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. American Journal of Hematology [Internet]. 2021;96(9):1131\u201336. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/ajh.26269","DOI":"10.1002\/ajh.26269"},{"key":"1728_CR35","doi-asserted-by":"crossref","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discovery [Internet]. 2024;10(1):55. Available from: https:\/\/www.nature.com\/articles\/s41420-024-01818-6","DOI":"10.1038\/s41420-024-01818-6"},{"key":"1728_CR36","doi-asserted-by":"crossref","unstructured":"Gu C, Wu L, Li X. IL-17 family: Cytokines, receptors and signaling. Cytokine [Internet]. 2013;64(2):477\u201385. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466613006388","DOI":"10.1016\/j.cyto.2013.07.022"},{"key":"1728_CR37","doi-asserted-by":"crossref","unstructured":"Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor\u2013based signaling and implications for disease. Nature Immunology [Internet]. 2019;20(12):1594\u2013602. Available from: https:\/\/www.nature.com\/articles\/s41590-019-0514-y","DOI":"10.1038\/s41590-019-0514-y"},{"key":"1728_CR38","doi-asserted-by":"publisher","unstructured":"Monin L, Gaffen SL. Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harbor Perspectives in Biology [Internet]. 2018;10(4):a028522. Available from: http:\/\/cshperspectives.cshlp.org\/lookup\/doi\/https:\/\/doi.org\/10.1101\/cshperspect.a028522","DOI":"10.1101\/cshperspect.a028522"},{"key":"1728_CR39","doi-asserted-by":"crossref","unstructured":"Huangfu L, Li R, Huang Y, Wang S. The IL-17 family in diseases: from bench to bedside. Signal Transduction and Targeted Therapy [Internet]. 2023;8(1):402. Available from: https:\/\/www.nature.com\/articles\/s41392-023-01620-3","DOI":"10.1038\/s41392-023-01620-3"},{"key":"1728_CR40","doi-asserted-by":"publisher","unstructured":"Numasaki M. Interleukin-17 promotes angiogenesis and tumor growth. Blood [Internet]. 2003;101(7):2620\u20137. Available from: http:\/\/www.bloodjournal.org\/cgi\/doi\/https:\/\/doi.org\/10.1182\/blood-2002-05-1461","DOI":"10.1182\/blood-2002-05-1461"},{"key":"1728_CR41","doi-asserted-by":"publisher","unstructured":"Wei L, Wang H, Yang F, Ding Q, Zhao J. Interleukin-17 potently increases non-small cell lung cancer growth. Molecular Medicine Reports [Internet]. 2016;13(2):1673\u201380. Available from: https:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/mmr.2015.4694","DOI":"10.3892\/mmr.2015.4694"},{"key":"1728_CR42","doi-asserted-by":"crossref","unstructured":"Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood [Internet]. 2009;114(2):357\u20139. Available from: https:\/\/ashpublications.org\/blood\/article\/114\/2\/357\/26199\/Endogenous-IL17-contributes-to-reduced-tumor","DOI":"10.1182\/blood-2008-09-177360"},{"key":"1728_CR43","doi-asserted-by":"crossref","unstructured":"Ngiow SF, Smyth MJ, Teng MWL. Does IL-17 suppress tumor growth? Blood [Internet]. 2010;115(12):2554\u20135. Available from: https:\/\/ashpublications.org\/blood\/article\/115\/12\/2554\/125915\/Does-IL17-suppress-tumor-growth","DOI":"10.1182\/blood-2009-11-254607"},{"key":"1728_CR44","doi-asserted-by":"crossref","unstructured":"Muranski P, Restifo NP. Does IL-17 promote tumor growth? Blood [Internet]. 2009;114(2):231\u20132. Available from: https:\/\/ashpublications.org\/blood\/article\/114\/2\/231\/26208\/Does-IL17-promote-tumor-growth","DOI":"10.1182\/blood-2009-04-215541"},{"key":"1728_CR45","doi-asserted-by":"crossref","unstructured":"Gasmi I, Machou C, Rodrigues A, Brouillet A, Nguyen TC, Rousseau B, et al. Interleukin-17 programs liver progenitor cell transformation into cancer stem cells through mir-122 downregulation with increased risk of primary liver cancer initiation. International Journal of Biological Sciences [Internet]. 2022;18(5):1944\u201360. Available from: https:\/\/www.ijbs.com\/v18p1944.htm","DOI":"10.7150\/ijbs.70408"},{"key":"1728_CR46","doi-asserted-by":"crossref","unstructured":"McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, et al. Oncogenic Kras Activates a Hematopoietic-to-Epithelial IL-17 Signaling Axis in Preinvasive Pancreatic Neoplasia. Cancer Cell [Internet]. 2014;25(5):621\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610814001226","DOI":"10.1016\/j.ccr.2014.03.014"},{"key":"1728_CR47","doi-asserted-by":"crossref","unstructured":"Pan B, Shen J, Cao J, Zhou Y, Shang L, Jin S, et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3\/GIV signaling pathway in non-small-cell lung cancer. Scientific Reports [Internet]. 2015;5(1):16053. Available from: https:\/\/www.nature.com\/articles\/srep16053","DOI":"10.1038\/srep16053"},{"key":"1728_CR48","doi-asserted-by":"crossref","unstructured":"Xiang T, Long H, He L, Han X, Lin K, Liang Z, et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene [Internet]. 2015;34(2):165\u2013176. Available from: https:\/\/www.nature.com\/articles\/onc2013537","DOI":"10.1038\/onc.2013.537"},{"key":"1728_CR49","doi-asserted-by":"publisher","unstructured":"Wang S, Wang G, Zhang L, Li F, Liu K, Wang Y, et al. Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells. Cell & Bioscience [Internet]. 2020;10(1):73. Available from: https:\/\/cellandbioscience.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13578-020-00431-1","DOI":"10.1186\/s13578-020-00431-1"},{"key":"1728_CR50","doi-asserted-by":"crossref","unstructured":"Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye A-M, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1\/2. Scientific Reports [Internet]. 2013;3(1):3456. Available from: https:\/\/www.nature.com\/articles\/srep03456","DOI":"10.1038\/srep03456"},{"key":"1728_CR51","doi-asserted-by":"publisher","unstructured":"Sui G, Qiu Y, Yu H, Kong Q, Zhen B. Interleukin\u201117 promotes the development of cisplatin resistance in colorectal cancer. Oncology Letters [Internet]. 2018; Available from: http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/ol.2018.9645","DOI":"10.3892\/ol.2018.9645"},{"key":"1728_CR52","doi-asserted-by":"publisher","unstructured":"Wang M, Wang L, Ren T, Xu L, Wen Z. IL-17A\/IL-17RA interaction promoted metastasis of osteosarcoma cells. Cancer Biology & Therapy [Internet]. 2013;14(2):155\u201363. Available from: http:\/\/www.tandfonline.com\/doi\/abs\/https:\/\/doi.org\/10.4161\/cbt.22955","DOI":"10.4161\/cbt.22955"},{"key":"1728_CR53","doi-asserted-by":"crossref","unstructured":"Yang J-Z, Li Y, Sun L-X, Fang J, Kong L-J, Zhang J-Q. Interleukin-17 receptor expression on vascular endothelial cells of masses of skeletal extramedullary disease in myeloma patients. Pathology - Research and Practice [Internet]. 2014;210(9):586\u201390. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033814001289","DOI":"10.1016\/j.prp.2014.04.018"},{"key":"1728_CR54","doi-asserted-by":"crossref","unstructured":"Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A, et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. European Journal of Internal Medicine [Internet]. 2006;17(6):412\u20136. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620506001117","DOI":"10.1016\/j.ejim.2006.02.012"},{"key":"1728_CR55","doi-asserted-by":"crossref","unstructured":"Lemancewicz D, Bolkun L, Jablonska E, Czeczuga-Semeniuk E, Kostur A, Kloczko J, et al. The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients. Medical Science Monitor [Internet]. 2012;18(1):BR54\u20139. Available from: http:\/\/www.medscimonit.com\/abstract\/index\/idArt\/882204","DOI":"10.12659\/MSM.882204"},{"key":"1728_CR56","doi-asserted-by":"crossref","unstructured":"Calcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nature Communications [Internet]. 2018;9(1):4832. Available from: https:\/\/www.nature.com\/articles\/s41467-018-07305-8","DOI":"10.1038\/s41467-018-07305-8"},{"key":"1728_CR57","doi-asserted-by":"crossref","unstructured":"Ben Hmid A, Selmi O, Rekik R, Lamari H, Zamali I, Ladeb S, et al. RORC overexpression as a sign of Th17 lymphocytes accumulation in multiple myeloma bone marrow. Cytokine [Internet]. 2020;134:155210. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104346662030226X","DOI":"10.1016\/j.cyto.2020.155210"},{"key":"1728_CR58","doi-asserted-by":"publisher","unstructured":"Braga WMT, Da Silva BR, De Carvalho AC, Maekawa YH, Bortoluzzo AB, Rizzatti EG, et al. FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells. Cancer Immunology, Immunotherapy [Internet]. 2014;63(11):1189\u201397. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s00262-014-1589-9","DOI":"10.1007\/s00262-014-1589-9"},{"key":"1728_CR59","doi-asserted-by":"publisher","unstructured":"Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T Regulatory Cells Are Associated with Adverse Clinical Features and Predict Progression in Multiple Myeloma. Rieux-Laucat F, editor. PLoS ONE [Internet]. 2012;7(10):e47077. Available from: https:\/\/dx.plos.org\/https:\/\/doi.org\/10.1371\/journal.pone.0047077","DOI":"10.1371\/journal.pone.0047077"},{"key":"1728_CR60","doi-asserted-by":"crossref","unstructured":"Chen X, Oppenheim JJ. Th17 cells and Tregs: unlikely allies. Journal of Leukocyte Biology [Internet]. 2014 Feb;95(5):723\u201331. Available from: https:\/\/academic.oup.com\/jleukbio\/article\/95\/5\/723\/6959501","DOI":"10.1189\/jlb.1213633"},{"key":"1728_CR61","doi-asserted-by":"publisher","unstructured":"Tucci M, Stucci S, Savonarola A, Ciavarella S, Cafforio P, Dammacco F, et al. Immature dendritic cells in multiple myeloma are prone to osteoclast\u2010like differentiation through interleukin\u201017 a stimulation. British Journal of Haematology [Internet]. 2013;161(6):821\u201331. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/bjh.12333","DOI":"10.1111\/bjh.12333"},{"key":"1728_CR62","doi-asserted-by":"publisher","unstructured":"Wang M, Chen P, Jia Y, He N, Li D, Ji C, et al. Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma. Oncotarget [Internet]. 2015;6(20):17958\u201367. Available from: https:\/\/www.oncotarget.com\/lookup\/doi\/https:\/\/doi.org\/10.18632\/oncotarget.4641","DOI":"10.18632\/oncotarget.4641"},{"key":"1728_CR63","doi-asserted-by":"crossref","unstructured":"Song X-N, Yang J-Z, Sun L-X, Meng J-B, Zhang J-Q, Lv H-Y, et al. Expression levels of IL-27 and IL-17 in multiple myeloma patients: A higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival. Leukemia Research [Internet]. 2013;37(9):1094\u201399. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002208","DOI":"10.1016\/j.leukres.2013.06.022"},{"key":"1728_CR64","doi-asserted-by":"crossref","unstructured":"Ma T, Zhang Y, Zhou X, Xie P, Li J. A Unique Role of T Helper 17 Cells in Different Treatment Stages of Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia [Internet]. 2020 Mar;20(3):190\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019322311","DOI":"10.1016\/j.clml.2019.12.009"},{"key":"1728_CR65","doi-asserted-by":"publisher","unstructured":"Shen C-J, Yuan Z-H, Liu Y-X, Hu G-Y. Increased Numbers of T Helper 17 Cells and the Correlation with Clinicopathological Characteristics in Multiple Myeloma. Journal of International Medical Research [Internet]. 2012 Apr;40(2):556\u201364. Available from: https:\/\/journals.sagepub.com\/doi\/https:\/\/doi.org\/10.1177\/147323001204000217","DOI":"10.1177\/147323001204000217"},{"key":"1728_CR66","doi-asserted-by":"publisher","unstructured":"Bai H, Wu S, Wang R, Xu J, Chen L. Bone marrow IRF4 level in multiple myeloma: an indicator of peripheral blood Th17 and disease. Oncotarget [Internet]. 2017 Oct;8(49):85392\u2013400. Available from: https:\/\/www.oncotarget.com\/lookup\/doi\/https:\/\/doi.org\/10.18632\/oncotarget.19907","DOI":"10.18632\/oncotarget.19907"},{"key":"1728_CR67","doi-asserted-by":"crossref","unstructured":"Gu J, Huang X, Zhang Y, Bao C, Zhou Z, Jin J. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. Cytokine [Internet]. 2021;138:155358. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466620303744","DOI":"10.1016\/j.cyto.2020.155358"},{"key":"1728_CR68","doi-asserted-by":"crossref","unstructured":"Li Y, Li D, Yan Z, Qi K, Chen L, Zhang Z, et al. Potential relationship and clinical significance of miRNAs and Th17 cytokines in patients with multiple myeloma. Leukemia Research [Internet]. 2014;38(9):1130\u20135. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212614002227","DOI":"10.1016\/j.leukres.2014.07.005"},{"key":"1728_CR69","doi-asserted-by":"crossref","unstructured":"Li Y, Zhang B, Li W, Wang L, Yan Z, Li H, et al. MiR-15a\/16 regulates the growth of myeloma cells, angiogenesis and antitumor immunity by inhibiting Bcl-2, VEGF-A and IL-17 expression in multiple myeloma. Leukemia Research [Internet]. 2016;49:73\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261630176X","DOI":"10.1016\/j.leukres.2016.08.013"},{"key":"1728_CR70","doi-asserted-by":"crossref","unstructured":"Prabhala RH, Fulciniti M, Pelluru D, Rashid N, Nigroiu A, Nanjappa P, et al. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma. Leukemia [Internet]. 2016;30(2):379\u201389. Available from: https:\/\/www.nature.com\/articles\/leu2015228","DOI":"10.1038\/leu.2015.228"},{"key":"1728_CR71","doi-asserted-by":"crossref","unstructured":"Tucci M, Stucci S, Passarelli A, D\u2019Oronzo S, Silvestris F. Everolimus restrains the IL-17A-dependent osteoclast-like transdifferentiation of dendritic cells in multiple myeloma. Experimental Hematology [Internet]. 2017;47:48\u201353. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16306592","DOI":"10.1016\/j.exphem.2016.10.004"},{"key":"1728_CR72","doi-asserted-by":"publisher","unstructured":"Thomas LW, Lee EB, Wu JJ. Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis. Journal of Dermatological Treatment [Internet]. 2019;30(2):110\u201316. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/09546634.2018.1473552","DOI":"10.1080\/09546634.2018.1473552"},{"key":"1728_CR73","doi-asserted-by":"publisher","unstructured":"Wendling D, Verhoeven F, Prati C. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opinion on Biological Therapy [Internet]. 2019;19(1):55\u201364. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/14712598.2019.1554053","DOI":"10.1080\/14712598.2019.1554053"},{"key":"1728_CR74","doi-asserted-by":"publisher","unstructured":"Wang J, Wang C, Liu L, Hong S, Ru Y, Sun X, et al. Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review. Frontiers in Immunology [Internet]. 2023;14:993057. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2023.993057\/full","DOI":"10.3389\/fimmu.2023.993057\/full"},{"key":"1728_CR75","doi-asserted-by":"crossref","unstructured":"Kim T-H, Kishimoto M, Wei JC-C, Jeong H, Nozaki A, Kobayashi S. Brodalumab, an anti\u2013interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. Rheumatology [Internet]. 2023;62(5):1851\u201359. Available from: https:\/\/academic.oup.com\/rheumatology\/article\/62\/5\/1851\/6709339","DOI":"10.1093\/rheumatology\/keac522"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01728-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01728-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:23Z","timestamp":1764917183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01728-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01728-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"10 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate."}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"194"}}